US · WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES · SMALL CAP
Can B Corp. NASC
9 fiscal years on record · USD · FY2023 reported
SEC FILINGS ONLY
Revenue · FY2023
$2.2M
▼ 67.8% vs FY2022
EPS · FY23
$-0.77
Dividend / sh · FY23
—
Payout · FY23
—
ROE · FY23
-1148.3%
Net margin · FY23
-451.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.2M
Revenue, FY2023 · full 9-year series below
Revenue
Net income
The company lost 452 cents on every revenue dollar this year.
Per share
USD -0.77
Diluted EPS, FY2023
EPS
The company pays no cash dividend.
Profitability
-1148.3%
Return on equity, FY2023
ROE
Operating margin-347.3%
Net margin-451.7%
Return on assets-75.8%
Each USD of equity lost 1148 cents this year.
Returned to shareholders
—
returned in FY2023 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+26.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+8.0%
+26.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2023
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 10.1M
total assets, end of FY2023
Total assetsUSD 10.1M
EquityUSD -1.0M
CashUSD 34,006.00
Current ratio0.48×
Equity funds -10% of total assets.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
·
−0.0
−0.0
−0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.77
−4.18
−9.06
−37.68
−2.20
−0.01
0.00
0.00
−0.02
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
−1148.3
−358.9
−343.0
−218.5
−116.4
−467.6
·
·
−3477.4
Shares out B
0.00
0.00
0.00
0.00
0.00
0.44
0.23
0.15
0.15
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
32 of 32
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed